H. Lundbeck AS
Latest From H. Lundbeck AS
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- H. Lundbeck AS
- Senior Management
Anders Götzsche, Interim CEO & EVP, CFO
Anders Gersel G Pederson, MD, EVP, R&D
Jacob Tolstrup, EVP, Commercial Operations
Keld Flintholm Jørgensen, EVP, CBO
- Contact Info
H. Lundbeck AS
Phone: (45) 3630 1311
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.